Asingle-center, retrospective, non-randomized chart review comparing readmission rates for patients who received rivaroxaban or enoxaparin for venous thromboembolism prophylaxis after total hip arthroplasty (THA) or total knee arthroplasty (TKA).

Trial Profile

Asingle-center, retrospective, non-randomized chart review comparing readmission rates for patients who received rivaroxaban or enoxaparin for venous thromboembolism prophylaxis after total hip arthroplasty (THA) or total knee arthroplasty (TKA).

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Rivaroxaban (Primary)
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jul 2016 New trial record
    • 01 Jun 2016 Results published in the P and T
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top